Kawada, T., Katayama, S., Yanagisawa, T., Mori, K., Fukuokaya, W., Komura, K., . . . group, O. b. o. J. s. Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy. Nature Portfolio.
Chicago Style (17th ed.) CitationKawada, Tatsushi, et al. Eosinophils as a Predictive Marker of Treatment-related Adverse Events in MRCC Patients Treated with First-line Immune-checkpoint Inhibitor Combination Therapy. Nature Portfolio.
MLA (9th ed.) CitationKawada, Tatsushi, et al. Eosinophils as a Predictive Marker of Treatment-related Adverse Events in MRCC Patients Treated with First-line Immune-checkpoint Inhibitor Combination Therapy. Nature Portfolio.
Warning: These citations may not always be 100% accurate.